Welcome to our dedicated page for Milestone Pharmaceuticals news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals stock.
Milestone Pharmaceuticals Inc. develops and commercializes cardiovascular medicines, centered on CARDAMYST (etripamil) nasal spray. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults. Etripamil is also being developed for symptomatic episodic attacks associated with AFib-RVR.
Company news commonly covers CARDAMYST commercialization, payer formulary access, real-world evidence work such as the RESET-PSVT registry, cardiovascular conference presentations, regulatory updates, financial results and business updates. Milestone also reports equity inducement grants and other corporate actions tied to its Nasdaq-listed common shares.
Milestone Pharmaceuticals (Nasdaq: MIST) will host a virtual Key Opinion Leader event on April 21, 2022, at 1:00 p.m. ET to discuss etripamil, its lead investigational product for treating paroxysmal supraventricular tachycardia (PSVT). Notable speakers include Bruce Stambler, MD, and Sean Pokorney, MD. The event will cover the PSVT treatment landscape, existing data on etripamil, and its commercial prospects. Etripamil aims to provide a self-administered rapid-response therapy for PSVT, potentially reducing emergency care needs.
Milestone Pharmaceuticals Inc. (MIST) reported its financial results for Q4 and the year ended December 31, 2021. The company had cash and equivalents of $114.1 million, down from $142.3 million the previous year. Research and development expenses rose significantly to $10.9 million in Q4, contributing to a total operating loss of $42.9 million for 2021. Milestone is focused on the upcoming Phase 3 RAPID trial results for its cardiovascular drug etripamil, with topline data expected mid-second half of 2022, targeting supraventricular tachycardia treatment.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced its participation in two upcoming investor conferences. Management will present at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 p.m. ET, and at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 11:20 a.m. ET. Live webcasts of these presentations will be available on Milestone's website, with archived replays accessible for 90 days post-event. Milestone focuses on innovative cardiovascular medicines, with its lead candidate, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia.
Milestone Pharmaceuticals (Nasdaq: MIST) appointed David Bharucha, M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022. Dr. Bharucha, a cardiac electrophysiologist with over 30 years of experience, replaces Francis Plat, M.D., who will transition to Chief Scientific Officer and serve in an advisory role post-Phase 3 RAPID trial. Dr. Bharucha aims to advance etripamil, a treatment for paroxysmal supraventricular tachycardia and atrial fibrillation. An inducement stock option for 330,000 shares has been granted to him, aligning his interests with shareholder value.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will participate in a prerecorded fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The chat will be available on January 10, 2022, at 7:00 am ET on Milestone's website. Milestone focuses on innovative cardiovascular medicines, with its lead product, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 trials for atrial fibrillation.
Milestone Pharmaceuticals (Nasdaq: MIST) announced significant findings from a post-hoc analysis of the Phase 3 NODE-301 trial for etripamil, a novel nasal spray treatment for paroxysmal supraventricular tachycardia (PSVT). The analysis revealed that etripamil significantly reduced heart rates during SVT episodes within 5 minutes, sustained for up to 60 minutes. Notably, patients experienced greater heart rate reductions compared to placebo (p<0.0001). These results, presented at the AHA Scientific Sessions 2021, support etripamil’s potential as an effective at-home treatment for PSVT and possibly atrial fibrillation with rapid ventricular response.
Milestone Pharmaceuticals (MIST) reported its Q3 2021 financial results, highlighting progress in the etripamil program for PSVT. The Phase 3 RAPID trial is on track to report topline data in H2 2022, targeting 180 adjudicated events among 500 patients. The recent PRO market research study revealed significant disease burden among PSVT patients, with a median of 12-15 episodes annually. The company holds $126.4 million in cash and reported a Q3 operating loss of $14.3 million, an increase from the previous year.
Milestone Pharmaceuticals (Nasdaq: MIST) announced presentations by CEO Joseph Oliveto at key investor conferences. The 2021 Jefferies London Virtual Healthcare Conference presentation becomes available on-demand on November 18, 2021, at 3:00 a.m. ET. Additionally, at the Piper Sandler 33rd Annual Virtual Healthcare Conference, a fireside chat will be accessible starting at 10:00 a.m. ET on November 22, 2021. Replays will be found on Milestone's website for approximately 30 days after the events, reinforcing their commitment to innovative cardiovascular medicine.
Milestone Pharmaceuticals (Nasdaq: MIST) has announced that Amit Hasija, CFO, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 29, 2021, at 10:00 a.m. ET. The presentation will occur virtually, and a live webcast can be accessed on Milestone's website, with an archived replay available afterward. Milestone is developing innovative cardiovascular medicines, including etripamil, which is in Phase 3 for treating paroxysmal supraventricular tachycardia and in Phase 2 for atrial fibrillation.
Milestone Pharmaceuticals (Nasdaq: MIST) announced that CEO Joseph Oliveto will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The chat will be pre-recorded and accessible from September 13, 2021, at 7:00 am ET on Milestone's website. Milestone focuses on innovative cardiovascular medicines, with its lead product candidate, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia and in Phase 2 trials for atrial fibrillation treatment.